Advertisement
IOVA vs VCYT
Which Stock Would AI Choose? Iovance Biotherapeutics (IOVA) vs. Veracyte (VCYT) Stock Comparison
Key Takeaways
- IOVA has delivered stronger year-to-date (YTD) gains of nearly 29%, fueled by commercial momentum for its Amtagvi cell therapy.
- VCYT stands out as profitable, with positive earnings per share (EPS) of $0.82 trailing twelve months (TTM) and guidance for 10-13% revenue growth in 2026.
- IOVA's market cap hovers around $1.5 billion with ongoing losses, contrasting VCYT's $2.7 billion cap and positive free cash flow.
- Both companies target oncology but differ in approach: IOVA via high-risk cell therapies versus VCYT's stable genomic diagnostics.
- Analyst price targets imply significant upside for both, with IOVA averaging around $9 and VCYT at $44-$46.
- Recent market activity shows volatility for IOVA amid pipeline catalysts, while VCYT exhibits steadier performance post-earnings.
Introduction
This stock comparison pits IOVA, a leader in tumor-infiltrating lymphocyte (TIL) therapies, against VCYT, a diagnostics specialist offering genomic classifiers for cancers like thyroid and prostate. Both operate in the competitive oncology space, appealing to growth-oriented traders and investors tracking biotech momentum. With recent earnings beats, pipeline advancements, and shifting market sentiment, this analysis highlights relative performance, financial health, and positioning in recent weeks. Traders seeking exposure to innovative cancer treatments may weigh IOVA's upside potential against VCYT's profitability in today's volatile biotech sector.
IOVA Overview and Recent Performance
Iovance Biotherapeutics (IOVA) develops autologous TIL cell therapies for advanced solid tumors, with its flagship product Amtagvi approved for metastatic melanoma. The company reported trailing twelve-month revenue of $263.5 million, reflecting 60% growth in 2025, driven by Amtagvi's rollout and 30% sequential revenue increase in Q4 2025. Stock performance has been robust YTD at +29%, with shares trading around $3.50 within a 52-week range of $1.64 to $5.63. Recent weeks saw volatility, including a pullback amid broader market pressures, but sentiment remains positive from analyst upgrades and targets up to $16. Key influences include commercial traction for Amtagvi, upcoming Q1 2026 earnings on May 7, and pipeline progress in NSCLC and other indications, boosting investor focus despite ongoing losses of -$391 million TTM.
VCYT Overview and Recent Performance
Veracyte (VCYT) provides precision oncology diagnostics, including the Afirma test for thyroid cancer and Decipher for prostate and bladder cancers. It achieved TTM revenue of $517 million and net income of $66 million, with EPS of $0.82. Shares trade near $33.50, up 20% YTD in a 52-week range of $22.61 to $50.71. Recent market activity reflects stability post-Q4 2025 earnings beat, where revenue hit $140.6 million and EPS reached $0.53, exceeding estimates. Management guided 10-13% revenue growth for 2026, supported by Decipher expansion and new launches like Prosigna. Analyst ratings lean "Strong Buy" with targets around $46, driven by profitability, $87 million in levered free cash flow TTM, and Q1 2026 results due May 5.
Trending AI Robots
Tickeron’s Trending AI Robots page showcases 25 top-performing AI trading bots curated from over 350 available agents that trade thousands of tickers across stocks, ETFs, and crypto. These bots employ diverse strategies like swing trading, trend following, volatility plays, and multi-agent systems, with timeframes from 5 minutes to 55 days. Featured bots display impressive stats, including annualized returns ranging from 15% to 176%, win rates of 54% to 88%, and profit factors up to 11.7. For instance, semiconductor-focused bots have achieved 98-120% returns with 64-74% win rates, while small-cap trend traders show 101% annualized gains. Ideal for current volatile conditions, these bots highlight risk-adjusted performance through metrics like profit-to-drawdown ratios averaging 6.5. Investors can explore and deploy them via paper trading or subscriptions to align with personalized strategies.
Head-to-Head Comparison
IOVA and VCYT both target cancer markets but diverge in business models: IOVA's therapy pipeline promises blockbuster potential yet carries manufacturing and regulatory risks, while VCYT's diagnostics deliver recurring revenue with lower execution hurdles. Growth drivers include IOVA's Amtagvi expansion and NSCLC data versus VCYT's test volume growth and MRD advancements. Recent momentum favors IOVA on YTD returns but with higher volatility (beta 0.76); VCYT (beta 1.96) offers stability via positive margins (13% profit margin). Risk factors weigh heavier on IOVA's cash burn versus VCYT's balance sheet strength. Market sentiment tilts bullish for both, though VCYT benefits from profitability in a risk-off environment.
Tickeron AI Verdict
Tickeron’s AI currently leans toward VCYT due to its trend consistency, profitability, and reaffirmed 2026 growth guidance amid biotech sector pressures. While IOVA shows stronger short-term momentum from Amtagvi catalysts, VCYT's positive EPS trajectory and free cash flow provide a more stable relative positioning, suggesting higher probability of outperformance in the near term.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer. Disclaimers and Limitations
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is IOVA is a Hold and VCYT is a Buy.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
IOVA’s FA Score shows that 0 FA rating(s) are green whileVCYT’s FA Score has 0 green FA rating(s).
- IOVA’s FA Score: 0 green, 5 red.
- VCYT’s FA Score: 0 green, 5 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
IOVA’s TA Score shows that 5 TA indicator(s) are bullish while VCYT’s TA Score has 5 bullish TA indicator(s).
- IOVA’s TA Score: 5 bullish, 5 bearish.
- VCYT’s TA Score: 5 bullish, 4 bearish.
Price Growth
IOVA (@Biotechnology) experienced а +16.17% price change this week, while VCYT (@Medical Specialties) price change was +5.64% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was +5.83%. For the same industry, the average monthly price growth was +1.96%, and the average quarterly price growth was +1945.11%.
The average weekly price growth across all stocks in the @Medical Specialties industry was +0.78%. For the same industry, the average monthly price growth was +3.12%, and the average quarterly price growth was -3.78%.
Reported Earning Dates
IOVA is expected to report earnings on Aug 06, 2026.
VCYT is expected to report earnings on Aug 11, 2026.
Industries' Descriptions
@Biotechnology (+5.83% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
@Medical Specialties (+0.78% weekly)Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.
| IOVA | VCYT | IOVA / VCYT | |
| Capitalization | 1.98B | 4.29B | 46% |
| EBITDA | -311.23M | 112M | -278% |
| Gain YTD | 62.553 | 27.767 | 225% |
| P/E Ratio | N/A | 49.25 | - |
| Revenue | 286M | 542M | 53% |
| Total Cash | 313M | 439M | 71% |
| Total Debt | 47.8M | 39.3M | 122% |
IOVA | VCYT | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 61 | 29 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 41 Fair valued | 64 Fair valued | |
PROFIT vs RISK RATING 1..100 | 100 | 73 | |
SMR RATING 1..100 | 99 | 81 | |
PRICE GROWTH RATING 1..100 | 40 | 37 | |
P/E GROWTH RATING 1..100 | 100 | 73 | |
SEASONALITY SCORE 1..100 | 90 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
IOVA's Valuation (41) in the Biotechnology industry is in the same range as VCYT (64). This means that IOVA’s stock grew similarly to VCYT’s over the last 12 months.
VCYT's Profit vs Risk Rating (73) in the Biotechnology industry is in the same range as IOVA (100). This means that VCYT’s stock grew similarly to IOVA’s over the last 12 months.
VCYT's SMR Rating (81) in the Biotechnology industry is in the same range as IOVA (99). This means that VCYT’s stock grew similarly to IOVA’s over the last 12 months.
VCYT's Price Growth Rating (37) in the Biotechnology industry is in the same range as IOVA (40). This means that VCYT’s stock grew similarly to IOVA’s over the last 12 months.
VCYT's P/E Growth Rating (73) in the Biotechnology industry is in the same range as IOVA (100). This means that VCYT’s stock grew similarly to IOVA’s over the last 12 months.
| IOVA | VCYT | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 81% | 2 days ago 90% |
| Stochastic ODDS (%) | 2 days ago 80% | 2 days ago 88% |
| Momentum ODDS (%) | 2 days ago 88% | 2 days ago 81% |
| MACD ODDS (%) | 2 days ago 90% | 2 days ago 79% |
| TrendWeek ODDS (%) | 2 days ago 88% | 2 days ago 76% |
| TrendMonth ODDS (%) | 2 days ago 83% | 2 days ago 80% |
| Advances ODDS (%) | 12 days ago 78% | 6 days ago 73% |
| Declines ODDS (%) | 8 days ago 87% | 12 days ago 80% |
| BollingerBands ODDS (%) | 2 days ago 90% | 2 days ago 88% |
| Aroon ODDS (%) | 2 days ago 86% | 2 days ago 81% |
Advertisement